

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT TO  
SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported) April 26, 2011

---

**BECTON, DICKINSON AND COMPANY**

(Exact Name of Registrant as Specified in Its Charter)

---

**New Jersey**

(State or Other Jurisdiction of Incorporation)

---

**001-4802**

(Commission File Number)

---

**22-0760120**

(IRS Employer Identification No.)

---

**1 Becton Drive, Franklin Lakes, New Jersey**

(Address of Principal Executive Offices)

---

**07417-1880**

(Zip Code)

---

**(201) 847-6800**

(Registrant's Telephone Number, Including Area Code)

---

**N/A**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

## ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On April 26, 2011, Becton, Dickinson and Company (“BD”) issued a press release announcing its financial results for its second fiscal quarter ending March 31, 2011. A copy of the press release is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (“non-GAAP measures”), as follows:

- Revenues. We present international and total revenue growth rates (for the total company and each of its business segments and units, and for our safety-engineered devices) after eliminating the effect of foreign currency translation, including gains or losses from our hedging activities. We believe that these measures of revenue growth allow investors to better understand the underlying operating results of BD and facilitate comparisons to prior periods.
- Earnings Per Share from Continuing Operations. We present our diluted earnings per share from continuing operations (“EPS”) for the second quarter and first six months of fiscal year 2010, and for the full fiscal year 2010, after eliminating the non-cash charge related to health care reform impacting Medicare Part D reimbursements. This item is not considered by management to be part of ordinary operations. Accordingly, we believe that these adjusted measures of EPS are more indicative of BD’s underlying performance for these periods, and allow investors to better assess our EPS guidance for fiscal year 2011. We also present our EPS growth for the second quarter and first six months of fiscal year 2011, and our EPS guidance for the full 2011 fiscal year, after eliminating the effect of foreign currency translation, including gains or losses from our hedging activities. We believe that eliminating the effect of foreign currency translation allows investors to better understand the underlying operating results of BD and facilitates comparisons to the prior year periods, and also allow investors to better understand BD’s EPS guidance.

BD’s management uses each of these non-GAAP measures in its own evaluation of BD’s performance, particularly when comparing performance to past periods. Management also uses the non-GAAP results for budget planning purposes on a quarterly and annual basis.

BD provides non-GAAP measures to investors on a supplemental basis, as they provide additional insight into BD’s financial results. Management believes the non-GAAP results provide a reasonable measure of BD’s underlying performance before the effects of items that are considered by management to be outside of BD’s underlying operational results or that affect period to period comparability.

Non-GAAP results should not be considered in isolation and are not in accordance with, or a substitute for, GAAP results. Our non-GAAP results may differ from similar measures used by other companies, even if similar terms are used to identify such measures. Although BD’s management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD’s net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. Investors should also consider these limitations when evaluating BD’s results.

---

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibit 99.1 Press release dated April 26, 2011, which is furnished pursuant to Item 2.02

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY  
(Registrant)

By: /s/ Gary DcFazio  
Gary DcFazio  
Vice President and Corporate Secretary

Date: April 26, 2011

---

Exhibit Index

99.1 Press release dated April 26, 2011, which is furnished pursuant to Item 2.02



Contact:

Monique N. Dolecki, Investor Relations — 201-847-5453  
Colleen T. White, Corporate Communications — 201-847-5369

**BD ANNOUNCES RESULTS FOR 2011 SECOND FISCAL QUARTER**

**Franklin Lakes, NJ (April 26, 2011)**— BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of \$1.922 billion for the second fiscal quarter ended March 31, 2011, representing an increase of 6.8 percent from the prior-year period. On a foreign currency-neutral basis, revenue increased 4.6 percent, despite an unfavorable comparison to the prior year of about 2.3 percentage points due to strong sales related to the H1N1 flu pandemic, supplemental spending in Japan and stimulus spending in the U.S. in fiscal year 2010.

“We are pleased with our solid results this quarter, which were in line with our expectations,” said Edward J. Ludwig, Chairman and Chief Executive Officer. “We continued the increased pace of our R&D spending and made strategic investments, such as our acquisition of Accuri Cytometers, demonstrating our commitment to driving revenue growth through innovation.”

**Update on Impact of Japan Earthquake and Tsunami**

Order volumes for BD products in Japan have now returned to normal levels. The Company’s manufacturing plant in Fukushima sustained some earthquake-related damage, but the prepared plated media manufacturing lines were recently restarted, and manufacturing of BD Hypak™ Prefillable Syringes is expected to resume during the third fiscal quarter 2011. BD’s Fukushima distribution center and an additional distribution center near Tokyo are in operation. The unfavorable impact of these events on the Company’s revenues in the second fiscal quarter was less than \$10 million. For the full fiscal year 2011, the Company anticipates these events to have an aggregate unfavorable impact of \$10 to \$20 million on revenues, or about \$0.05 per share, which has been incorporated into its fiscal year 2011 guidance.

### **Update on the Acquisition of Accuri Cytometers, Inc.**

As announced in March 2011, the Company completed the acquisition of Accuri Cytometers, Inc, an Ann Arbor, Michigan-based company that develops and manufactures personal flow cytometers for researchers. The financial impact of the acquisition on fiscal year 2011 earnings has been incorporated into the Company's previously disclosed guidance.

### **Second Quarter and Six-Month Fiscal 2011 Operating Results**

Reported diluted earnings per share for the second quarter were \$1.38, compared with \$1.18 in the prior-year period, representing a 16.9 percent increase. The prior-year period included a non-cash charge of \$8.9 million, or \$0.04 per share, related to healthcare reform impacting Medicare Part D reimbursements. Excluding that item, earnings per share from continuing operations increased by 13.1 percent, compared with adjusted diluted earnings per share from continuing operations of \$1.22 in the prior-year period, or 7.4 percent on a currency-neutral basis.

For the six-month period ending March 31, 2011, reported diluted earnings per share from continuing operations were \$2.72, compared with \$2.43 in the prior-year period. Excluding the aforementioned charge, diluted earnings per share from continuing operations increased by 10.1 percent, compared with adjusted diluted earnings per share of \$2.47 in the prior-year period, or 5.3 percent on a currency-neutral basis.

### **Segment Results**

In the BD Medical segment, worldwide revenues for the quarter were \$981 million, representing an increase of 6.5 percent compared with the prior-year period, or 4.9 percent on a foreign currency-neutral basis. Revenues reflected strong sales of Diabetes Care and Pharmaceutical Systems products. The segment's revenues also reflected an unfavorable comparison to the prior year of about 1.6 percentage points due to strong sales related to the H1N1 flu pandemic in fiscal year 2010. For the six-month period ended March 31, 2011, BD Medical revenues increased 0.8 percent, or 0.1 percent on a foreign currency-neutral basis.

In the BD Diagnostics segment, worldwide revenues for the quarter were \$605 million, representing an increase of 8.9 percent compared with the prior-year period, or 6.5 percent on a foreign currency-neutral basis. Revenues reflected solid growth in Preanalytical Systems safety-engineered products and strong growth in Diagnostic Systems infectious disease platforms. For the six-month period ended March 31, 2011, BD Diagnostics revenues increased 4.9 percent, or 3.6 percent on a foreign currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were \$335 million, representing an increase of 4.1 percent compared with the prior-year period, or 0.4 percent on a foreign currency-neutral basis. Segment revenue growth was negatively impacted by about 12 percentage points due to certain factors. About 8 percentage points of the impact was due to an unfavorable comparison resulting from strong sales related to supplemental spending in Japan and stimulus spending in the U.S. in fiscal year 2010, and about 3 percentage points resulted from the effects of the earthquake and tsunami in Japan. Segment growth was driven primarily by instrument and reagent sales in the Cell Analysis unit. Discovery Labware revenues in the U.S. were negatively impacted by weakness in core consumables due to lower pharmaceutical spending and academic sector sales. For the six-month

period ended March 31, 2011, BD Biosciences revenues increased by 3.9 percent, or 1.9 percent on a foreign currency-neutral basis.

#### **Geographic Results**

Second quarter revenues in the U.S. were \$829 million, representing an increase of 4.7 percent compared with the prior-year period. Revenues outside of the U.S. were \$1.093 billion, representing an increase of 8.5 percent compared with the prior-year period, or 4.6 percent on a foreign currency-neutral basis. Revenues reflected continued strength in emerging markets, which was partially offset by weakened demand in Western Europe due to challenging macroeconomic conditions. For the six-month period ended March 31, 2011, revenues in the U.S. were \$1.658 billion, representing an increase of 0.8 percent compared with the prior-year period. Revenues outside of the U.S. were \$2.106 billion, representing an increase of 4.1 percent compared with the prior-year period, or 2.1 percent on a foreign currency-neutral basis.

#### **Fiscal Year 2011 Outlook**

The Company is raising its reported revenue guidance for the full fiscal year 2011 to an increase of approximately 5 to 6 percent compared with fiscal year 2010, due to an expected favorable currency impact. On a foreign currency-neutral basis, the Company is lowering its revenue guidance to an increase of about 3.5 percent versus its previous guidance of about 4 percent, mainly due to lower than expected sales in Western Europe.

The Company is raising its previous guidance for reported diluted earnings per share from continuing operations for fiscal year 2011 by about \$0.10 per share to a range of \$5.55 to \$5.65, an increase of approximately 13 to 15 percent over fiscal year 2010. This revised guidance reflects the anticipated effects of favorable currency and operating efficiencies, partially offset by higher resin costs and the negative impact of the Japan earthquake and tsunami. Diluted earnings per share from continuing operations for fiscal year 2011 are expected to increase 12 to 14 percent over adjusted diluted earnings per share from continuing operations of \$4.94, excluding the specified item, for fiscal year 2010. The specified item represents the aforementioned 2010 non-cash charge of \$0.04 per share related to healthcare reform. On a currency-neutral basis, the Company expects diluted earnings per share from continuing operations to increase about 10 percent over adjusted diluted earnings per share in the prior-year period.

#### **Conference Call Information**

A conference call regarding BD's second quarter results and its expectations for the full fiscal year 2011 will be broadcast live on BD's website [www.bd.com/investors](http://www.bd.com/investors), along with related slides, at 10:00 a.m. (ET) Wednesday, April 27, 2011. The slides are available concurrent with the issuance of this press release at [www.bd.com/investors](http://www.bd.com/investors). The conference call will be available for replay on BD's website, [www.bd.com/investors](http://www.bd.com/investors), or at 1-800-642-1687 (domestic) and 1-706-645-9291 (international) through the close of business on Wednesday, May 4, 2011, access code 59468691.

#### **Non-GAAP Financial Measures**

This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables.



## **About BD**

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit [www.bd.com](http://www.bd.com).

\*\*\*

*This press release, including the section entitled "Fiscal Year 2011 Outlook", contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues and earnings per share. Forward-looking statements may be identified by the use of words such as "expect", "estimate" or words of similar meaning in conjunction with statements of future performance. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. These factors include, but are not limited to: the potential adverse effects that the earthquake and tsunami in Japan and the situation regarding the Fukushima, Japan nuclear power plant may have on BD's future operations in Japan; the unknown consequences of the recently-enacted healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for BD's products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic situation on BD's ability to access credit markets and finance its operations, the demand for BD's products and services, or its suppliers' ability to provide products needed for BD's operations; changes in interest or foreign currency exchange rates; competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; new or changing laws impacting BD's business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; BD's ability to successfully integrate any businesses it acquires; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission. BD does not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.*

BECTON DICKINSON AND COMPANY  
CONSOLIDATED INCOME STATEMENTS  
(Unaudited; Amounts in thousands, except per share data)

	2011	Three Months Ended March 31, 2010	% Change
REVENUES	\$1,922,023	\$1,799,409	6.8
Cost of products sold	920,589	864,492	6.5
Selling and administrative	441,942	421,076	5.0
Research and development	119,152	100,193	18.9
TOTAL OPERATING COSTS AND EXPENSES	1,481,683	1,385,761	6.9
OPERATING INCOME	440,340	413,648	6.5
Interest income	14,564	9,652	50.9
Interest expense	(23,921)	(12,913)	85.2
Other (expense) income, net	(2,522)	164	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	428,461	410,551	4.4
Income tax provision	117,399	125,517	(6.5)
INCOME FROM CONTINUING OPERATIONS	311,062	285,034	9.1
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF \$377 AND \$4,101, RESPECTIVELY	957	12,597	(92.4)
NET INCOME	\$ 312,019	\$ 297,631	4.8
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 1.41	\$ 1.21	16.5
Income from discontinued operations	\$ —	\$ 0.05	NM
Net income	\$ 1.41	\$ 1.26	11.9
Diluted:			
Income from continuing operations	\$ 1.38	\$ 1.18	16.9
Income from discontinued operations	\$ —	\$ 0.05	NM
Net income (1)	\$ 1.38	\$ 1.24	11.3
AVERAGE SHARES OUTSTANDING			
Basic	220,894	235,325	
Diluted	225,467	240,863	

NM — Not Meaningful

(1) Total per share amounts may not add due to rounding

BECTON DICKINSON AND COMPANY  
CONSOLIDATED INCOME STATEMENTS  
(Unaudited; Amounts in thousands, except per share data)

	2011	Six Months Ended March 31, 2010	% Change
REVENUES	\$3,764,028	\$3,668,227	2.6
Cost of products sold	1,786,020	1,758,816	1.5
Selling and administrative	889,897	866,749	2.7
Research and development	234,693	199,344	17.7
TOTAL OPERATING COSTS AND EXPENSES	2,910,610	2,824,909	3.0
OPERATING INCOME	853,418	843,318	1.2
Interest income	29,786	18,441	61.5
Interest expense	(39,474)	(25,900)	52.4
Other expense, net	(7,118)	(2,190)	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	836,612	833,669	0.4
Income tax provision	211,273	244,542	(13.6)
INCOME FROM CONTINUING OPERATIONS	625,339	589,127	6.1
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF \$601 AND \$8,718, RESPECTIVELY	2,617	24,880	(89.5)
NET INCOME	\$ 627,956	\$ 614,007	2.3
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 2.79	\$ 2.49	12.0
Income from discontinued operations	\$ 0.01	\$ 0.11	(90.9)
Net income	\$ 2.80	\$ 2.60	7.7
Diluted:			
Income from continuing operations	\$ 2.72	\$ 2.43	11.9
Income from discontinued operations	\$ 0.01	\$ 0.10	(90.0)
Net income (1)	\$ 2.74	\$ 2.53	8.3
AVERAGE SHARES OUTSTANDING			
Basic	224,528	236,353	
Diluted	229,529	242,327	

NM — Not Meaningful

(1) Total per share amounts may not add due to rounding

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY SEGMENT AND GEOGRAPHIC AREA  
(Unaudited; Amounts in thousands)

	2011	Three Months Ended March 31, 2010	% Change
<b>BD MEDICAL</b>			
United States	\$ 398,487	\$ 381,767	4.4
International	582,845	539,866	8.0
<b>TOTAL</b>	<b>\$ 981,332</b>	<b>\$ 921,633</b>	<b>6.5</b>
<b>BD DIAGNOSTICS</b>			
United States	\$ 310,617	\$ 292,841	6.1
International	294,730	262,831	12.1
<b>TOTAL</b>	<b>\$ 605,347</b>	<b>\$ 555,672</b>	<b>8.9</b>
<b>BD BIOSCIENCES</b>			
United States	\$ 120,077	\$ 117,151	2.5
International	215,267	204,953	5.0
<b>TOTAL</b>	<b>\$ 335,344</b>	<b>\$ 322,104</b>	<b>4.1</b>
<b>TOTAL REVENUES</b>			
United States	\$ 829,181	\$ 791,759	4.7
International	1,092,842	1,007,650	8.5
<b>TOTAL</b>	<b>\$1,922,023</b>	<b>\$1,799,409</b>	<b>6.8</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY SEGMENT AND GEOGRAPHIC AREA  
(Unaudited; Amounts in thousands)

	2011	Six Months Ended March 31, 2010	% Change
<b>BD MEDICAL</b>			
United States	\$ 804,014	\$ 814,344	(1.3)
International	1,103,863	1,077,959	2.4
<b>TOTAL</b>	<b>\$1,907,877</b>	<b>\$1,892,303</b>	<b>0.8</b>
<b>BD DIAGNOSTICS</b>			
United States	\$ 619,467	\$ 603,045	2.7
International	587,603	548,102	7.2
<b>TOTAL</b>	<b>\$1,207,070</b>	<b>\$1,151,147</b>	<b>4.9</b>
<b>BD BIOSCIENCES</b>			
United States	\$ 234,302	\$ 227,787	2.9
International	414,779	396,990	4.5
<b>TOTAL</b>	<b>\$ 649,081</b>	<b>\$ 624,777</b>	<b>3.9</b>
<b>TOTAL REVENUES</b>			
United States	\$1,657,783	\$1,645,176	0.8
International	2,106,245	2,023,051	4.1
<b>TOTAL</b>	<b>\$3,764,028</b>	<b>\$3,668,227</b>	<b>2.6</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended March 31,  
(Unaudited; Amounts in thousands)

	United States		% Change
	2011	2010	
<b>BD MEDICAL</b>			
Medical Surgical Systems	\$234,571	\$237,174	(1.1)
Diabetes Care	95,939	92,515	3.7
Pharmaceutical Systems	67,977	52,078	30.5
<b>TOTAL</b>	<b>\$398,487</b>	<b>\$381,767</b>	<b>4.4</b>
<b>BD DIAGNOSTICS</b>			
Preanalytical Systems	\$156,978	\$149,932	4.7
Diagnostic Systems	153,639	142,909	7.5
<b>TOTAL</b>	<b>\$310,617</b>	<b>\$292,841</b>	<b>6.1</b>
<b>BD BIOSCIENCES</b>			
Cell Analysis	\$ 83,006	\$ 78,183	6.2
Discovery Labware	37,071	38,968	(4.9)
<b>TOTAL</b>	<b>\$120,077</b>	<b>\$117,151</b>	<b>2.5</b>
<b>TOTAL UNITED STATES</b>	<b>\$829,181</b>	<b>\$791,759</b>	<b>4.7</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended March 31, (continued)  
(Unaudited; Amounts in thousands)

			International		
	2011	2010	Reported	% Change FXN	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 270,020	\$ 244,090	10.6	5.7	4.9
Diabetes Care	111,820	\$ 95,471	17.1	12.4	4.7
Pharmaceutical Systems	201,005	\$ 200,305	0.3	1.2	(0.9)
<b>TOTAL</b>	<b>\$ 582,845</b>	<b>\$ 539,866</b>	<b>8.0</b>	<b>5.3</b>	<b>2.7</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 149,261	\$ 137,738	8.4	3.9	4.5
Diagnostic Systems	145,469	125,093	16.3	10.7	5.6
<b>TOTAL</b>	<b>\$ 294,730</b>	<b>\$ 262,831</b>	<b>12.1</b>	<b>7.1</b>	<b>5.0</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 172,510	\$ 164,292	5.0	(0.5)	5.5
Discovery Labware	42,757	40,661	5.2	(1.6)	6.8
<b>TOTAL</b>	<b>\$ 215,267</b>	<b>\$ 204,953</b>	<b>5.0</b>	<b>(0.8)</b>	<b>5.8</b>
<b>TOTAL INTERNATIONAL</b>	<b>\$1,092,842</b>	<b>\$1,007,650</b>	<b>8.5</b>	<b>4.6</b>	<b>3.9</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended March 31, (continued)  
(Unaudited; Amounts in thousands)

			Total		
	2011	2010	Reported	% Change FXN	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 504,591	\$ 481,264	4.8	2.3	2.5
Diabetes Care	207,759	187,986	10.5	8.1	2.4
Pharmaceutical Systems	268,982	252,383	6.6	7.3	(0.7)
<b>TOTAL</b>	<b>\$ 981,332</b>	<b>\$ 921,633</b>	<b>6.5</b>	<b>4.9</b>	<b>1.6</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 306,239	\$ 287,670	6.5	4.4	2.1
Diagnostic Systems	299,108	268,002	11.6	9.0	2.6
<b>TOTAL</b>	<b>\$ 605,347</b>	<b>\$ 555,672</b>	<b>8.9</b>	<b>6.5</b>	<b>2.4</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 255,516	\$ 242,475	5.4	1.7	3.7
Discovery Labware	79,828	79,629	0.2	(3.3)	3.5
<b>TOTAL</b>	<b>\$ 335,344</b>	<b>\$ 322,104</b>	<b>4.1</b>	<b>0.4</b>	<b>3.7</b>
<b>TOTAL REVENUES</b>	<b>\$1,922,023</b>	<b>\$1,799,409</b>	<b>6.8</b>	<b>4.6</b>	<b>2.2</b>



BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Six Months Ended March 31,  
(Unaudited; Amounts in thousands)

	United States		
	2011	2010	% Change
<b>BD MEDICAL</b>			
Medical Surgical Systems	\$ 488,825	\$ 511,166	(4.4)
Diabetes Care	195,524	189,079	3.4
Pharmaceutical Systems	119,665	114,099	4.9
<b>TOTAL</b>	<b>\$ 804,014</b>	<b>\$ 814,344</b>	<b>(1.3)</b>
<b>BD DIAGNOSTICS</b>			
Preanalytical Systems	\$ 319,036	\$ 306,167	4.2
Diagnostic Systems	300,431	296,878	1.2
<b>TOTAL</b>	<b>\$ 619,467</b>	<b>\$ 603,045</b>	<b>2.7</b>
<b>BD BIOSCIENCES</b>			
Cell Analysis	\$ 163,262	\$ 155,787	4.8
Discovery Labware	71,040	72,000	(1.3)
<b>TOTAL</b>	<b>\$ 234,302</b>	<b>\$ 227,787</b>	<b>2.9</b>
<b>TOTAL UNITED STATES</b>	<b>\$ 1,657,783</b>	<b>\$ 1,645,176</b>	<b>0.8</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Six Months Ended March 31, (continued)  
(Unaudited; Amounts in thousands)

	2011	2010	International		
			Reported	% Change FXN	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 528,491	\$ 503,273	5.0	1.7	3.3
Diabetes Care	226,118	200,428	12.8	10.5	2.3
Pharmaceutical Systems	349,254	374,258	(6.7)	(4.4)	(2.3)
<b>TOTAL</b>	<b>\$ 1,103,863</b>	<b>\$ 1,077,959</b>	<b>2.4</b>	<b>1.2</b>	<b>1.2</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 299,832	\$ 281,670	6.4	3.9	2.5
Diagnostic Systems	287,771	266,432	8.0	4.8	3.2
<b>TOTAL</b>	<b>\$ 587,603</b>	<b>\$ 548,102</b>	<b>7.2</b>	<b>4.4</b>	<b>2.8</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 332,997	\$ 318,025	4.7	1.9	2.8
Discovery Labware	81,782	78,965	3.6	(0.9)	4.5
<b>TOTAL</b>	<b>\$ 414,779</b>	<b>\$ 396,990</b>	<b>4.5</b>	<b>1.4</b>	<b>3.1</b>
<b>TOTAL INTERNATIONAL</b>	<b>\$ 2,106,245</b>	<b>\$ 2,023,051</b>	<b>4.1</b>	<b>2.1</b>	<b>2.0</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Six Months Ended March 31, (continued)  
(Unaudited; Amounts in thousands)

	2011	2010	Total		
			Reported	% Change FXN	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$1,017,316	\$1,014,439	0.3	(1.4)	1.7
Diabetes Care	421,642	389,507	8.3	7.1	1.2
Pharmaceutical Systems	468,919	488,357	(4.0)	(2.2)	(1.8)
<b>TOTAL</b>	<b>\$1,907,877</b>	<b>\$1,892,303</b>	<b>0.8</b>	<b>0.1</b>	<b>0.7</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 618,868	\$ 587,837	5.3	4.1	1.2
Diagnostic Systems	588,202	563,310	4.4	2.9	1.5
<b>TOTAL</b>	<b>\$1,207,070</b>	<b>\$1,151,147</b>	<b>4.9</b>	<b>3.6</b>	<b>1.3</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 496,259	\$ 473,812	4.7	2.8	1.9
Discovery Labware	152,822	150,965	1.2	(1.1)	2.3
<b>TOTAL</b>	<b>\$ 649,081</b>	<b>\$ 624,777</b>	<b>3.9</b>	<b>1.9</b>	<b>2.0</b>
<b>TOTAL REVENUES</b>	<b>\$3,764,028</b>	<b>\$3,668,227</b>	<b>2.6</b>	<b>1.5</b>	<b>1.1</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
SAFETY REVENUES  
(Unaudited; Amounts in thousands)

	Three Months Ended March 31,				
	2011	2010	% Change		
			Reported	FXN	FX Impact
<b>TOTAL SAFETY REVENUES</b>					
United States	\$ 263,524	\$ 263,044	0.2	0.2	—
International	177,859	148,537	19.7	14.1	5.6
<b>TOTAL</b>	<b>\$ 441,383</b>	<b>\$ 411,581</b>	<b>7.2</b>	<b>5.2</b>	<b>2.0</b>
<b>BY SEGMENT</b>					
BD Medical	\$ 204,866	\$ 193,688	5.8	3.9	1.9
BD Diagnostics	236,517	217,893	8.5	6.3	2.2
<b>TOTAL</b>	<b>\$ 441,383</b>	<b>\$ 411,581</b>	<b>7.2</b>	<b>5.2</b>	<b>2.0</b>

	Six Months Ended March 31,				
	2011	2010	% Change		
			Reported	FXN	FX Impact
<b>TOTAL SAFETY REVENUES</b>					
United States	\$ 547,306	\$ 554,859	(1.4)	(1.4)	—
International	347,113	303,666	14.3	10.8	3.5
<b>TOTAL</b>	<b>\$ 894,419</b>	<b>\$ 858,525</b>	<b>4.2</b>	<b>2.9</b>	<b>1.3</b>
<b>BY SEGMENT</b>					
BD Medical	\$ 418,175	\$ 414,862	0.8	(0.4)	1.2
BD Diagnostics	476,244	443,663	7.3	6.0	1.3
<b>TOTAL</b>	<b>\$ 894,419</b>	<b>\$ 858,525</b>	<b>4.2</b>	<b>2.9</b>	<b>1.3</b>

BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL INFORMATION  
 FY2011 Quarter-to-Date Reconciliation  
 (Unaudited; Amounts in millions, except per share data)

	Three Months Ended March 31,				
	Reported FY 2011	Reported FY 2010	Tax (1)	Adjusted FY 2010	Adjusted % Growth
Diluted Earnings per Share from Continuing Operations	\$ 1.38	\$ 1.18	\$ .04	\$ 1.22	13.1%

(1) Represents a non-cash charge related to healthcare reform impacting Medicare Part D reimbursements.

BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL INFORMATION  
 FY2011 Year-to-Date Reconciliation  
 (Unaudited; Amounts in millions, except per share data)

	Six Months Ended March 31,				
	Reported FY 2011	Reported FY 2010	Tax (1)	Adjusted FY 2010	Adjusted % Growth
Diluted Earnings per Share from Continuing Operations	\$ 2.72	\$ 2.43	\$ .04	\$ 2.47	10.1%

(1) Represents a non-cash charge related to healthcare reform impacting Medicare Part D reimbursements.

BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL INFORMATION  
 Quarter-to-Date Fiscal 2011 Reconciliation — FX Impact  
 (Unaudited; Amounts in millions, except per share data)

	Three Months Ended March 31,							
	Reported FY 2011	Adjusted FY 2010	Adjusted Growth \$	Foreign Currency Translation	FY10 Hedge Loss	Total FX	Adjusted FXN Change	FXN Growth
REVENUES	\$ 1,922	1,799	123	13	27	40	83	4.6%
Diluted Earnings per Share from Continuing Operations	\$ 1.38	1.22	0.16	(0.00)	0.07	0.07	0.09	7.4%

*All figures rounded. Totals may not add due to rounding.*

BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL INFORMATION  
 Year-to-Date Fiscal 2011 Reconciliation — FX Impact  
 (Unaudited; Amounts in millions, except per share data)

	Six Months Ended March 31,							
	Reported FY 2011	Adjusted FY 2010	Adjusted Growth \$	Foreign Currency Translation	FY10 Hedge Loss	Total FX	Adjusted FXN Change	FXN Growth
REVENUES	\$ 3,764	3,668	96	(1)	41	41	55	1.5%
Diluted Earnings per Share from Continuing Operations	\$ 2.72	2.47	0.25	0.01	0.11	0.12	0.13	5.3%

*All figures rounded. Totals may not add due to rounding.*



BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
FY2010 Year-to-Date Reconciliation

Reported Diluted Earnings per Share from Continuing Operations	\$ 4.90
Tax (1)	0.04
Adjusted Diluted Earnings per Share from Continuing Operations	<u>\$ 4.94</u>

(1) Represents a non-cash charge related to healthcare reform impacting Medicare Part D reimbursements.